A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.

Lipid imbalance triggered by Snail-driven epithelial–mesenchymal transition creates a cholesterol-dependent vulnerability ...

ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced that it has entered into a collaboration agreement with Fosun Kairos ...

NeuroScientific Biopharmaceuticals’ stem cell tech has delivered real-world promise for those with Crohn’s disease, ...

We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

Under the terms of the agreement, EUDA expects to invest up to RMB 6 million in two tranches, consisting of an initial tranche of RMB 1 million and a second tranche of RMB 5 million, subject to the ...

Stem cell treatment targeting the bone beneath the knee reduced pain and improved movement more effectively than joint ...

Scientists uncovered how the protein Piezo1 translates physical activity into stronger bones, offering a path to ...

Mesoblast (MESO) stock jumps as the company's lead asset Ryoncil adds $35.1M in revenue during the December quarter, marking ...

Immorta Bio Inc., a scientific longevity company dedicated to Treating Diseases of Aging and Treating Aging as Disease™, today announced new data demonstrating that its combination therapy of SenoVax™ ...

The increase in quarterly revenues continues to strengthen Mesoblast's balance sheet after the Company announced it entered into a US$125 million facility with its largest shareholder which ...

Early success with a treatment for a form of Crohn's Disease has sent Neuroscientific Biopharmaceuticals shares higher.